Skip to content

Study · Non-randomized trial · n = 28 · 1994

2 results

Lack of involvement of the cholinergic mechanism in vasoactive intestinal peptide- and peptide-histidine methionine-induced growth hormone (GH) responses in acromegaly: comparison with the GH responses to thyrotropin-releasing hormone and GH-releasing hormone.

Watanobe H, Habu S, Nasushita R, Takebe K

Neuropeptides1 Aug 1994

PMID7991070 (opens in a new tab)DOI10.1016/0143-4179(94)90047-7 (opens in a new tab)PepBankPUB-07991070
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In 28 patients with active acromegaly, an intravenous VIP bolus produced a significant GH increase in 13 patients (46%).

    In plain wordsIn people with active acromegaly, VIP raised growth hormone in about half of the patients.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseGH response to VIP (responders)
    Study

    n = 28

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · intravenous bolusAs given in this study (human).

    Measurements

    Responders
    13 patients
    VIP
    Responders
    46%
    VIP

    Source sentences

    Summary
    In response to TRH, GHRH, VIP and PHM, 23 (82%), 24 (86%), 13 (46%) and 7 (25%) patients, respectively, responded with a significant GH increase (> 50% and 6 micrograms/l above the basal level).
    1 context sentence
    Summary · context
    28 patients with active acromegaly underwent i.v. bolus injections of thyrotropin-releasing hormone (TRH, 500 micrograms), GH-releasing hormone (GHRH, 100 micrograms), VIP (100 micrograms), and PHM (100 micrograms) with or without a prior atropine treatment (1 mg, i.m., 30 min before).

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism

    In patients with acromegaly who responded to VIP, atropine pretreatment did not significantly suppress the GH response to VIP.

    In plain wordsIn people with acromegaly, atropine did not block the growth hormone rise after VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeEffect of atropine pretreatment on VIP-induced GH response (area under curve)
    Study

    n: not reported in source

    Comparator
    No atropine pretreatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    When the GH responses were estimated by the area under the response curve, the atropine pretreatment was able to significantly suppress the GH response to GHRH, but not to TRH, VIP, or PHM.
    1 context sentence
    Summary · context
    28 patients with active acromegaly underwent i.v. bolus injections of thyrotropin-releasing hormone (TRH, 500 micrograms), GH-releasing hormone (GHRH, 100 micrograms), VIP (100 micrograms), and PHM (100 micrograms) with or without a prior atropine treatment (1 mg, i.m., 30 min before).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.